CSIMarket
 
Celyad Oncology Sa  (CYAD)
Other Ticker:  
 
 
Price: $0.4700 $-0.06 -11.103%
Day's High: $0.528 Week Perf: -20.34 %
Day's Low: $ 0.47 30 Day Perf: -25.4 %
Volume (M): 49 52 Wk High: $ 0.96
Volume (M$): $ 23 52 Wk Avg: $0.72
Open: $0.52 52 Wk Low: $0.47



 Market Capitalization (Millions $) 11
 Shares Outstanding (Millions) 23
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) 34
 Capital Exp. (TTM) (Millions $) 0

Celyad Oncology Sa
Celyad Oncology SA is a biopharmaceutical company based in Belgium. It focuses on the development of innovative CAR-T cell therapies for the treatment of cancer. CAR-T cell therapy is a cutting-edge immunotherapy approach that uses a patient's own immune cells to recognize and destroy cancer cells. Celyad Oncology's unique CAR-T platform, known as CAR-T NKR-2, is designed to target a protein called NKG2D, which is found on the surface of cancer cells. By targeting NKG2D, CAR-T NKR-2 aims to enhance the immune system's ability to recognize and eliminate cancer cells. The company is dedicated to advancing its pipeline of CAR-T therapies for multiple types of cancer, with a focus on improving patient outcomes and quality of life.


   Company Address: Rue Edouard Belin 2 Mont-Saint-Guibert 1435
   Company Phone Number: 10 394 100   Stock Exchange / Ticker: NASDAQ CYAD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Affimed N V

Affimed N.V. Faces Worsening Deficit in Financial Fourth Quarter of 2023

/>Affimed N.V., a leading clinical-stage immuno-oncology company, recently released its financial results for the fiscal year 2023. These results highlight a significant decline in revenue and an increased net loss per share compared to the previous year. However, despite the challenging financial performance, Affimed has also provided an update on the promising clinical response data for its AFM24-102 trial in treating EGFRwt NSCLC. This article will explore the potential impact of these financial results and the implications for Affimed's future.
Disastrous Financials:
In the fiscal fourth quarter of 2023, Affimed N.V. reported a disastrous financial performance, with revenue fading by 79.99% to $9.27 million and a net loss per share widening to $-7.94 from the corresponding quarter a year ago. The company's net deficit for the quarter amounted to $-118.651 million, surpassing the $-96.324 million deficit of the previous year.

Pds Biotechnology Corp

PDS Biotechnology Corp Shows Significant Improvement in Operating Deficit in Fourth Quarter of 2023



The recent financial results of PDS Biotechnology Corp, a clinical-stage immunotherapy company specializing in targeted immunotherapies for cancer and infectious diseases, have garnered interest among industry experts. An analysis of the company's fourth-quarter earnings in 2023 reveals a notable reduction in the operating deficit compared to the previous year. This positive trend indicates that PDS Biotechnology is making significant progress in its business strategy and operational efficiency. Moreover, the company's recent announcement of inducement stock options to their new CFO, Lars Boesgaard, further highlights its commitment to attracting and retaining top talent to support future growth.
Improved Financial Performance:
In the October to December 31, 2023 reporting period, PDS Biotechnology's operating deficit was recorded at $-10.406961 million, a significant improvement compared to the $-18.821351 million deficit in the same quarter of the previous year. This reduction in deficit is a significant milestone for the company, reflecting its efforts in increasing operational efficiency.

Chemomab Therapeutics Ltd

Among many companies, the CMMB disclosed also its fourth quarter of 2023 performance



As the October to December 31, 2023 reporting season continues, the Major Pharmaceutical Preparations sector is generating significant attention. Among the prominent players in this sector, Chemomab Therapeutics Ltd recently disclosed its operating deficit for the most recent fiscal period, indicating a clear transition towards profitability. Moreover, the company has achieved a remarkable feat by being granted a new European patent for its groundbreaking monoclonal antibody, CM-101. This patent extension not only strengthens the company's intellectual property portfolio but also highlights the immense potential of CM-101 as a therapeutic solution for liver diseases, particularly Primary Sclerosing Cholangitis (PSC). This article aims to explore the implications of this patent grant and its potential impacts on the future performance of Chemomab Therapeutics.
Background:
Primary Sclerosing Cholangitis is a chronic liver disease characterized by progressive inflammation and fibrosis of the bile ducts, which could ultimately lead to liver failure. Unfortunately, there are limited treatment options available for PSC patients, creating an urgent need for innovative interventions. In response, Chemomab developed CM-101, a first-in-class monoclonal antibody that has exhibited promising results in preclinical studies. As of now, CM-101 has progressed to Phase 2 of clinical development specifically for the treatment of PSC.

Monopar Therapeutics Inc

Between many corporations, the MNPR issued as well the fourth quarter of 2023 numbers

Investors in the stock market have something to celebrate as the October to December 31, 2023 reporting cycle resumes. Numerous corporations, including those in the Major Pharmaceutical Preparations industry, have announced their earnings, and one company that stands out is Monopar Therapeutics Inc. (Nasdaq: MNPR).
Despite facing some challenges, Monopar Therapeutics has shown resilience and determination in its day-to-day operations, resulting in a significant improvement in its financial performance compared to the previous year. In the fourth quarter of 2023, the company reported an operating shortfall of $-1.911988 million, which is a clear improvement over the $-2.896 million reported in the same period of 2022.

Casi Pharmaceuticals Inc

Looking into fourth quarter of 2023 numbers, the Major Pharmaceutical Preparations company's saw a stunning -21.407 %, in revenue

Casi Pharmaceuticals Inc. is a biopharmaceutical company that is dedicated to developing and commercializing innovative therapeutics and pharmaceutical products. The company recently reported its financial results for the fiscal three months ending December 31, 2023, which showed a decline in business and an increase in deficit. This has caused concern among investors and stakeholders as the company continues to face challenges in the market.
During this fiscal quarter, Casi Pharmaceuticals Inc.'s deficit per share increased to $-2.02 from $-3.01, while revenue declined by -21.41% to $33.88 million from $43.11 million in the previous year. The company also reported a net deficit of $-26.259 million, compared to a deficit of $-40.257 million in the same quarter a year ago. These financial results paint a bleak picture for the company's performance in the current market.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com